Lyell Immunopharma (LYEL) Competitors $1.10 0.00 (0.00%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LYEL vs. ADCT, VERV, BLUE, ALEC, ACHL, BCAX, ARDX, CALT, BCYC, and APLTShould you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include ADC Therapeutics (ADCT), Verve Therapeutics (VERV), bluebird bio (BLUE), Alector (ALEC), Achilles Therapeutics (ACHL), Bicara Therapeutics (BCAX), Ardelyx (ARDX), Calliditas Therapeutics AB (publ) (CALT), Bicycle Therapeutics (BCYC), and Applied Therapeutics (APLT). These companies are all part of the "medical" sector. Lyell Immunopharma vs. ADC Therapeutics Verve Therapeutics bluebird bio Alector Achilles Therapeutics Bicara Therapeutics Ardelyx Calliditas Therapeutics AB (publ) Bicycle Therapeutics Applied Therapeutics Lyell Immunopharma (NASDAQ:LYEL) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability. Is LYEL or ADCT more profitable? ADC Therapeutics has a net margin of -300.00% compared to Lyell Immunopharma's net margin of -323,792.09%. ADC Therapeutics' return on equity of 0.00% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% ADC Therapeutics -300.00%N/A -61.33% Which has stronger earnings and valuation, LYEL or ADCT? Lyell Immunopharma has higher earnings, but lower revenue than ADC Therapeutics. Lyell Immunopharma is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$130K2,362.63-$234.63M-$0.79-1.39ADC Therapeutics$69.56M3.32-$240.05M-$2.39-1.00 Which has more volatility & risk, LYEL or ADCT? Lyell Immunopharma has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Do analysts rate LYEL or ADCT? Lyell Immunopharma presently has a consensus target price of $1.00, suggesting a potential downside of 9.09%. ADC Therapeutics has a consensus target price of $8.25, suggesting a potential upside of 245.19%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in LYEL or ADCT? 66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LYEL or ADCT? ADC Therapeutics received 41 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 66.27% of users gave ADC Therapeutics an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1448.28% Underperform Votes1551.72% ADC TherapeuticsOutperform Votes5566.27% Underperform Votes2833.73% Does the media favor LYEL or ADCT? In the previous week, Lyell Immunopharma had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Lyell Immunopharma and 3 mentions for ADC Therapeutics. Lyell Immunopharma's average media sentiment score of 0.49 beat ADC Therapeutics' score of 0.28 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryADC Therapeutics beats Lyell Immunopharma on 10 of the 18 factors compared between the two stocks. Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYEL vs. The Competition Export to ExcelMetricLyell ImmunopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$307.14M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-1.394.7865.5913.48Price / Sales2,362.63377.381,278.7587.67Price / CashN/A51.2039.7035.24Price / Book0.589.686.475.93Net Income-$234.63M$154.43M$119.73M$225.73M7 Day Performance-9.84%-9.46%-5.13%-1.34%1 Month Performance-6.78%-7.27%-2.71%1.15%1 Year Performance-43.30%28.13%31.08%24.02% Lyell Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYELLyell Immunopharma0.4859 of 5 stars$1.10flat$1.00-9.1%-41.2%$307.14M$130,000.00-1.39270Analyst ForecastADCTADC Therapeutics2.8286 of 5 stars$2.93flatN/A+275.8%$283.30M$69.56M-1.15310Short Interest ↓VERVVerve Therapeutics2.3056 of 5 stars$6.31-0.8%N/A-56.4%$534.21M$11.76M-2.57110Analyst RevisionBLUEbluebird bio2.8835 of 5 stars$0.41+6.2%N/A-89.4%$78.67M$54.90M-0.18323Upcoming EarningsAnalyst DowngradeNews CoverageALECAlector4.3865 of 5 stars$5.75+2.0%N/A+3.2%$563.12M$61.51M-3.38270News CoverageGap UpACHLAchilles Therapeutics2.5399 of 5 stars$1.05+0.5%N/A+36.4%$43.14MN/A-0.66250Short Interest ↓News CoverageBCAXBicara Therapeutics3.5886 of 5 stars$23.82+0.9%N/AN/A$1.23BN/A0.0032Earnings ReportAnalyst RevisionNews CoverageARDXArdelyx4.0429 of 5 stars$5.07-20.5%N/A+23.3%$1.20B$124.46M-16.90267Short Interest ↑Analyst RevisionGap UpHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)0.1943 of 5 stars$40.00-0.4%N/AN/A$1.19B$1.60B-21.62180News CoverageBCYCBicycle Therapeutics2.8616 of 5 stars$24.96+1.1%N/A+55.8%$1.19B$36.90M-7.59240Insider SellingShort Interest ↑APLTApplied Therapeutics4.4519 of 5 stars$10.09+3.6%N/A+338.9%$1.16B$-333,000.00-6.3130Short Interest ↓News Coverage Related Companies and Tools Related Companies ADCT Alternatives VERV Alternatives BLUE Alternatives ALEC Alternatives ACHL Alternatives BCAX Alternatives ARDX Alternatives CALT Alternatives BCYC Alternatives APLT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LYEL) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
